Characterization of Flagella Produced by Clinical Strains of Stenotrophomonas maltophilia
Doroti de Oliveira-Garcia*†, Monique Dall'Agnol‡, Mónica Rosales‡, Ana C.G.S. Azzuz§, Marina B. Martinez†§, and Jorge A. Girón‡
Author affiliations: *Laboratório Clínico do Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; †Departamento de Microbiologia do Instituto de Ciências Biomédicas da Universidade de São Paulo, São Paulo, Brazil; ‡Benemerita Universidad Autónoma de Puebla, Puebla, México; §Departamento de Análises Clínicas da Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, São Paulo, Brazil;
Figure 5. Identification of the 38-kDa flagellin protein SMFliC in clinical isolates of Stenotrophomonas maltophilia. Lane 1, SMDP14; lane 2, SMDP275; lane 3, SMHC176; lane 4, SMHC181; lane 5, SMDP315; lane 6, SMDP314; and lane 7, SMHC179. Lane 8, the purified SMFliC, was used as positive control. The immunoblot shows the presence of the 38-kDa flagellin protein in all the isolates. Doublet bands were seen in some of the isolates. Molecular weight standards and the 38-kDa flagellin protein are indicated by arrows.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.